Skip to content

A prospective, randomized, controlled, multicenter clinical study of radical prostatectomy immediately after prostate biopsy

A prospective, randomized, controlled, multicenter clinical study of radical prostatectomy immediately after prostate biopsy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058915
Enrollment
Unknown
Registered
2022-04-19
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatic cancer

Interventions

experimental group :Radical prostatectomy was performed 1 week after prostatectomy
control group :Radical prostatectomy is performed 4-6 weeks after prostatocentesis

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Subjects voluntarily participate and sign the informed consent form; 2. Age = 75 years; 3. Patients diagnosed as prostate cancer by biopsy pathology, including low risk and medium risk patients; Localized high-risk prostate cancer; 4. The patient's life expectancy is long and the overall health condition allows surgery; 5. Transrectal biopsy; 6. Laparoscopic radical prostatectomy via extraperitoneal approach; 7. No other surgical contraindication.

Exclusion criteria

Exclusion criteria: 1. Special treatment (endocrine therapy, radiotherapy and chemotherapy, etc.) from puncture to operation; 2. Those who are easy to lose the interview after operation; 3. Patients with other malignant tumors; 4. Surgical patients with median incision of lower abdomen.

Design outcomes

Primary

MeasureTime frame
time of operation;peroperative bleeding;Urine control rate 3 months after operation;

Secondary

MeasureTime frame
PSA at 6 weeks, 3 months and 6 months postoperatively;Preoperative psychological status of patients (General Hospital Anxiety and Depression Scale);Margin positive rate;Proportion of adjuvant therapy (radiotherapy, endocrine therapy) required;

Countries

China

Contacts

Public ContactWang wenguang

The First Affiliated Hospital of Xinjiang Medical University

wwg0903@163.com+86 13659917670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026